Fulgent Genetics, Inc.
FLGT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.02 | -0.09 | 0.07 |
| FCF Yield | -3.45% | 0.56% | 26.19% | 17.40% |
| EV / EBITDA | -10.45 | -5.28 | 3.93 | 4.10 |
| Quality | ||||
| ROIC | -5.43% | -16.75% | 10.39% | 42.06% |
| Gross Margin | 37.82% | 36.12% | 59.28% | 78.29% |
| Cash Conversion Ratio | -0.48 | -0.15 | 1.79 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.92% | -33.70% | 13.65% | 9,975,118.64% |
| Free Cash Flow Growth | -501.48% | -97.96% | -54.39% | 394.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.95 | 0.56 | -0.19 | -0.21 |
| Interest Coverage | -434.81 | -400.67 | 176.24 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 21.02 | 0.00 | 58.89 | 17.66 |
| Cash Conversion Cycle | 78.52 | 42.15 | 17.05 | 38.66 |